← Browse by Condition
Medical Condition

allogeneic hematopoietic cell transplant

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT03394365 Phase 3
Recruiting

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Enrollment
115 pts
Location
United States, Austr...
Sponsor
Pierre Fabre Medicament
View Trial →